mRNA vaccines to fight C. difficile infections
Official title: mVACS--mRNA Vaccines for C. difficile Suppression
Funded at University of Pennsylvania · NIH-11037943 · Data updated 2026-11-12
This study is working on a new type of vaccine using mRNA technology, like the COVID-19 vaccines, to help prevent and treat infections from Clostridioides difficile, which can be a serious health issue, and they’ve seen good results in animals so far!
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Pennsylvania NIH-funded |
| Lab location | 1 site (Philadelphia, United States) |
| Project start | March 1, 2023 |
| Project end | February 29, 2028 |
| Funding year | 2025 |
| Award (this year) | $1,529,954 |
| NIH project number | 5U19AI174998-03 |
| Project ID | NIH-11037943 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research include individuals who have experienced recurrent C. difficile infections or are at high risk for such infections.
✕Less likely to help
Patients who have never been infected with C. difficile or those with contraindications to vaccination may not benefit from this research.
What this research studies
This research focuses on developing innovative mRNA vaccines aimed at preventing and treating infections caused by Clostridioides difficile, a significant public health threat. The approach utilizes modified mRNA technology, similar to that used in COVID-19 vaccines, to create a vaccine that targets the toxins produced by C. difficile. The research team has already demonstrated promising results in animal models, showing that their vaccine formulation can provide protection against lethal doses of the bacteria. However, further improvements are needed to enhance its effectiveness and ensure complete clearance of the infection.
Why it matters
Potential benefit: If successful, this research could lead to an effective vaccine that significantly reduces the incidence and recurrence of C. difficile infections in patients.
How similar studies have gone: Other research has shown success with mRNA vaccine technology in combating infectious diseases, particularly with COVID-19, indicating a promising avenue for similar approaches against C. difficile.
Where this research is happening
-
University of Pennsylvania
Philadelphia, United States Active
Researchers
- Principal investigator: Bushman, Frederic D — University of Pennsylvania
- Study coordinator: Bushman, Frederic D
Related research
Other NIH-funded projects on the same topics.
-
Comparing universal and guideline-directed genetic testing for young adults with cancer
This study is looking at whether a broader genetic test can help young adults with cancer find inherited risks that regular tests might miss, so they can get better treatment and care tailored just for them.
-
Better, searchable data for human pain biology
A data integration center will standardize, combine, and share molecular and cellular data from human pain research to help scientists understand how pain works and to accelerate discoveries.
-
Understanding how sweat glands form and work to help burn and skin injury patients
A study at the University of Pennsylvania looks at how sweat glands develop and function, with the goal of informing treatments for people who suffer traumatic skin injuries.
-
Cardiovascular risk planning and reduction for men with prostate cancer
A program to better predict and reduce heart disease risk in men treated for prostate cancer, especially older patients.
-
Understanding how a special airway cell helps protect and repair breathing passages
A researcher is studying a newly found airway cell called the hillock to see how it protects the airways and helps repair them after injury, with the aim of helping people with asthma, COPD, or bronchiectasis.
-
Defining TMJ cartilage progenitors and their regulatory niche for TMJ regeneration
Researchers are studying the cells that could help repair the jaw’s cartilage in TMJ osteoarthritis to lay the groundwork for regenerative therapies.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.